Bret J Musser Selected Research

casirivimab and imdevimab drug combination

10/2022	Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
9/2022	Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.
1/2022	Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
12/2021	REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.
9/2021	Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
6/2021	Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention.
1/2021	REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
1/2021	Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bret J Musser Research Topics

Disease

9	COVID-19 10/2022 - 01/2021
3	Infections 01/2022 - 01/2021
3	Type 2 Diabetes Mellitus (MODY) 11/2014 - 04/2010
2	Asymptomatic Infections 09/2021 - 01/2021
1	Pneumonia (Pneumonitis) 01/2022
1	Hypersensitivity (Allergy) 01/2021
1	Diarrhea 04/2010
1	Hypoglycemia (Reactive Hypoglycemia) 04/2010
1	Constipation 04/2010
1	Cardiotoxicity 12/2008
1	Weight Loss (Weight Reduction) 01/2008
1	Obesity 01/2008

Drug/Important Bio-Agent (IBA)

8	casirivimab and imdevimab drug combinationIBA 10/2022 - 01/2021
6	Monoclonal AntibodiesIBA 10/2022 - 01/2021
2	Metformin (Glucophage)FDA LinkGeneric 06/2011 - 04/2010
1	COVID-19 VaccinesIBA 10/2022
1	sarilumabIBA 01/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022
1	AntibodiesIBA 01/2022
1	Glycoproteins (Glycoprotein)IBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	Immunoglobulin IsotypesIBA 01/2022
1	InterleukinsIBA 01/2022
1	Antiviral Agents (Antivirals)IBA 09/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2021
1	Neutralizing AntibodiesIBA 01/2021
1	Glucagon Receptors (Glucagon Receptor)IBA 11/2014
1	Gliclazide (Diamicron)IBA 06/2011
1	glimepiride (Amarel)FDA LinkGeneric 06/2011
1	Glyburide (Glibenclamide)FDA LinkGeneric 06/2011
1	Sitagliptin Phosphate (Januvia)FDA Link 04/2010
1	Digoxin (Digitek)FDA LinkGeneric 12/2008
1	EtoricoxibIBA 12/2008
1	CannabinoidsIBA 01/2008
1	N- (3- (4- chlorophenyl)- 2- (3- cyanophenyl)- 1- methylpropyl)- 2- methyl- 2- ((5- (trifluoromethyl)pyridin- 2- yl)oxy)propanamideIBA 01/2008

Therapy/Procedure

2	Therapeutics 01/2022 - 01/2008
1	Artificial Respiration (Mechanical Ventilation) 01/2022
1	Subcutaneous Injections 01/2021